BNTXBioNTech SESigning up patients
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 75 (planned)
- Started
- Jan 15, 2026
- Main results expected
- Jan 2028
- Fully finished
- Jul 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed overall response rate (ORR)
Measured over: Up to 24 months
Occurrence of treatment emergent adverse events (TEAEs) by severity
Measured over: From the first dose of study treatment until 90 days after the last dose of study treatment (up to 27 months)
Occurrence of dose interruptions, reductions or discontinuations of study treatment due to TEAEs
Measured over: Up to 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07297212 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC